Arcutis Biotherapeutics announced the Food and Drug Administration has approved the supplemental new drug application, or sNDA, for Zoryve cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, according to Drug Store News, or DSN. “Arcutis intends to make Zoryve cream 0.15% widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of July. The company said it is dedicated to ensuring predictable access for the Zoryve portfolio of products, with one simple copay and fulfillment process,” according to DSN.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
- Arcutis announces new long-term data from study of roflumilast in AD
- Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Soars on Dermatological Treatments Launch
- Ventyx Biosciences announces appointment of Moore as COO
Questions or Comments about the article? Write to editor@tipranks.com